The Pharmaceuticals Division focuses on prescription products, especially for women’s healthcare and cardiology, and also on specialty therapeutics in the areas of oncology, haematology and ophthalmology. The division also comprises the Radiology Business Unit which markets contrast-enhanced diagnostic imaging equipment together with the necessary contrast agents.

With our innovative products, we seek to achieve a significant therapeutic benefit for patients, while at the same time satisfying the growing requirements of physicians and health insurers.

In the medium term, our recently launched products such as Xarelto™, Eylea™, Stivarga™, Xofigo™ and Adempas™ in particular should contribute to increased sales. To safeguard our growth in the long term, we will be further expanding our early-stage research activities and driving forward the clinical development of active ingredient candidates discovered in-house. Moreover, we will continue to systematically supplement our development portfolio by means of licensing agreements and acquisitions.